Rosa M Giraldez-Perez | Intracellular Transport Systems | Innovative Research Award

Published on by Cell Biologist

Prof. Dr. Rosa M Giraldez-Perez | Intracellular Transport Systems | Innovative Research Award

University or Cordoba | Spain

Rosa María Giráldez-Pérez is a researcher in the fields of nanotechnology, nanomedicine, physiology, and neuroscience whose scientific contributions focus on the design and application of nanomaterials for therapeutic purposes. Her work has addressed innovative strategies such as gold nanosystems functionalized with antibiotics or anticancer drugs, the development of nanocarriers for leukemia, prostate, liver, and lung cancer treatments, as well as nanoparticle-based approaches to prevent antibiotic resistance. She has also contributed to research in obesity therapy through nanosystems targeting metabolic regulation and in neuroscience through studies on oxidative stress and fragile X syndrome. Her research output includes 81 scientific documents, which have accumulated 911 citations and reflect an h-index of 13, demonstrating both productivity and impact in her field. A significant portion of her publications are in high-impact journals indexed in the Journal Citation Reports (JCR), and several list her as first or senior author, highlighting her leading role in collaborative projects. By integrating expertise from cellular biology, physiology, and nanoscience, her work advances translational biomedical research and offers potential therapeutic solutions for cancer, infectious diseases, metabolic disorders, and neurological conditions.

Profiles: Orcid | Scopus

Featured Publications:

Giráldez-Pérez, R. M., Grueso, E. M., Montero-Hidalgo, A. J., Muriana-Fernández, C., Kuliszewska, E., Luque, R. M., & Prado-Gotor, R. (2025). Daunomycin nanocarriers with high therapeutic payload for the treatment of childhood leukemia. Pharmaceutics, 17(9), 1236.

De Diego-Otero, Y., El Bekay, R., García-Guirado, F., Sánchez-Salido, L., & Giráldez-Pérez, R. M. (2024). Apocynin, a selective NADPH oxidase (Nox2) inhibitor, ameliorates behavioural and learning deficits in the fragile X syndrome mouse model. Biomedicines, 12(2887).

Lhamyani, S., Gentile, A. M., Mengual-Mesa, M., Grueso, E., Giráldez-Pérez, R. M., Fernandez-Garcia, J. C., … El Bekay, R. (2024). Au@16-pH-16/miR-21 mimic nanosystem: An efficient treatment for obesity through browning and thermogenesis induction. Biomedicine & Pharmacotherapy, 171, 116104.

Giráldez-Pérez, R. M., Grueso-Molina, E. M., Carbonero-Martínez, A., Álvarezmárquez, J., Kuliszewska, E., Gordillo-Macías, M., & Prado-Gotor, R. (2023). Synergistic antibacterial effects of amoxicillin and gold nanoparticles: A therapeutic option to combat antibiotic resistance. Antibiotics, 12(8), 81275.

Giráldez-Pérez, R. M., Grueso, E., Montero-Hidalgo, A. J., Luque, R. M., Carnerero, J. M., Kuliszewska, E., & Prado-Gotor, R. (2022). Gold nanosystems covered with doxorubicin/DNA complexes: A therapeutic target for prostate and liver cancer. International Journal of Molecular Sciences, 23(24), 15575.

Giráldez-Pérez, R. M., Grueso, E. M., Jiménez-Aguayo, R., Carbonero, A., González-Bravo, M., Kuliszewska, E., & Prado-Gotor, R. (2022). Use of nanoparticles to prevent resistance to antibiotics: Synthesis and characterization of gold nanosystems based on tetracycline. Pharmaceutics, 14(9), 1941.

Lhamyani, S., Gentile, A. M., Giráldez-Pérez, R. M., et al. (2021). miR-21 mimic blocks obesity in mice: A novel therapeutic option. Molecular Therapy – Nucleic Acids, 26, 401–416. h

Grueso-Molina, E. M., Giráldez-Pérez, R. M., Kuliszewska, E., Guerrero, J. A., & Prado-Gotor, R. (2021). Reversible cationic gemini surfactant-induced aggregation of anionic gold nanoparticles for sensing biomolecules. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 610, 125893.

Gomes, A., Carnerero-Panduro, J. M., Jiménez-Ruiz, A., Grueso-Molina, E. M., Giráldez-Pérez, R. M., & Prado-Gotor, R. (2021). Lysozyme-AuNPs interactions: Determination of binding free energy. Nanomaterials, 11(8), 2139.

Giráldez-Pérez, R. M., Grueso-Molina, E. M., Domínguez-García, I., Pastor-Carrillo, N. M., Kuliszewska, E., & Prado-Gotor, R. (2021). Biocompatible DNA/5-fluorouracil gemini surfactant-functionalized gold nanoparticles as promising vectors in lung cancer therapy. Pharmaceutics, 13(3), 423.

PANAGIOTA TSIATSIOU | Host-Pathogen Interactions | Best Researcher Award

Published on by Cell Biologist

Dr. PANAGIOTA TSIATSIOU | Host-Pathogen Interactions | Best Researcher Award

Dr. PANAGIOTA TSIATSIOU, AHEPA UNIVERSITY HOSPITAL, Greece

Dr. Panagiota Tsiatsiou is a dedicated medical biopathologist with over two decades of service in the Greek National Health System. Born on March 17, 1969, in Thessaloniki, Greece, she earned her M.D. from the Aristotle University of Thessaloniki and has specialized in hematology diagnostics, molecular biology, and public health. Since 2011, she has served in the Hematology Section at AHEPA University Hospital and was appointed Director in 2018. Her role extends beyond diagnostics to include leadership, training of residents, and managing lab operations, especially during the COVID-19 pandemic. With three Master’s degrees and active participation in scientific publications and conferences, Dr. Tsiatsiou continues to bridge clinical practice and research. Her work on angiopoietins and biomarkers in COVID-19 patients demonstrates her commitment to innovative healthcare solutions and translational medicine.

Publication Profile: 

Scopus

Orcid

✅ Strengths for the Award:

  1. Extensive Clinical and Laboratory Expertise
    Over 20 years of experience in microbiology and hematology laboratories, with advanced specialization in Medical Biopathology, PCR techniques, and molecular hematology.

  2. Research Impact in COVID-19
    Lead author in two recent international peer-reviewed publications (2024, 2025) on angiopoietins and endothelial damage in COVID-19—topics of significant relevance in post-pandemic biomedical research.

  3. Academic Qualifications
    Holder of three Master’s degrees in Health Services Management, Public Health, and Biomedical Sciences—demonstrating a strong interdisciplinary foundation and commitment to academic excellence.

  4. Mentorship and Leadership
    Director of the Hematology Section at AHEPA University Hospital since 2018; deeply involved in resident training and lab coordination, especially during the pandemic, proving strong leadership under crisis.

  5. Scientific Contribution

    • 6 publications (4 international, 2 Greek)

    • 99 scientific papers

    • Participation in 158 scientific conferences, workshops, and seminars—highlighting strong engagement with the research community.

⚠️ Areas for Improvement:

  1. Global Visibility
    While research quality is high, international recognition could be improved by targeting higher-impact journals and expanding collaborations outside Greece.

  2. Grants and Funding Leadership
    CV does not specify involvement in research grant acquisition or project funding management—which are often critical metrics in high-level research awards.

  3. Innovation and Patents
    There is no mention of patents, technological innovation, or industry partnerships, which could further enhance her scientific portfolio.

  4. Broader Publication Scope
    Expanding beyond COVID-19-related studies to publish more widely in hematologic and molecular diagnostics would strengthen her long-term research narrative.

🎓 Education:

Dr. Tsiatsiou holds a solid educational background in medicine and public health. She completed her M.D. at the Aristotle University of Thessaloniki (1988–1995), followed by rural service and specialization in Medical Biopathology at Theageneio Anticancer Hospital, obtaining her board certification in 2002. She pursued a Master’s in Health Services Management (2005–2008) at the Hellenic Open University, focusing on blood donor psychology. She furthered her expertise with a Master’s in Public Health at the National School of Public Health, where she studied foodborne infections. Additionally, she obtained a Master’s in Biomedical Sciences with a concentration in Diagnosis and Therapy, focusing on genetic mutations like FV Leiden. Her academic trajectory reflects a deep interdisciplinary approach—combining clinical knowledge, health systems, and research.

🏥 Experience:

Dr. Tsiatsiou’s clinical career spans more than 20 years, primarily within Greece’s National Health System. From 2003 to 2020, she served in various microbiology labs, refining her diagnostic skills. Since July 2011, she has worked in the Hematology Section at AHEPA University Hospital, leading the unit since 2018. Her expertise includes hemostasis, hemoglobinopathies, and molecular testing, and she has been instrumental in staff training and lab management. She led the hemostasis lab during the COVID-19 pandemic, ensuring continuity and quality of diagnostics under pressure. Her dedication to resident education in both Medical Biopathology and General Medicine has made her a respected mentor. Dr. Tsiatsiou’s leadership has elevated the lab’s scientific output, and her involvement in over 150 conferences showcases her engagement with ongoing medical developments.

🔬 Research Focus:

Dr. Tsiatsiou’s research is centered on hematology diagnostics, hemostasis disorders, and molecular markers in infectious diseases. Her most recent work investigates endothelial damage and angiopoietin levels as predictors in COVID-19 patients during the Delta and Omicron waves. This research bridges laboratory medicine with clinical outcomes, offering vital insights into disease severity and prognostics. She also explores genetic predispositions, such as FV Leiden mutations, in thrombotic risk profiling. Her postgraduate theses and training in PCR and molecular hematology underscore her commitment to translational science. With 6 peer-reviewed publications and 99 scientific papers, her academic output is diverse and impactful. Dr. Tsiatsiou’s multidimensional research contributes not only to hematology but also to public health and epidemiology, making her work highly relevant in modern medicine and worthy of recognition.

📚 Publications Top Notes:

  1. 📄 Biomarkers of Endothelial Damage and Disease Severity in COVID-19 Patients, Current Issues in Molecular Biology, 2025

  2. 📄 Angiopoietins as Predictor Indexes in COVID-19 Patients in Delta and Omicron Waves, Current Issues in Molecular Biology, 2024

  3. 📄 Thesis: Trends, Attitudes, and Motivations of Blood Donors and Non-Donors – Hellenic Open University

  4. 📄 Thesis: Foodborne Infections in Urban and Rural Populations of Central Macedonia – National School of Public Health

  5. 📄 Thesis: Prevalence of FV Leiden Mutation in a Tertiary Hospital – Democritus University of Thrace & IHU

  6. 📄 Additional 99 scientific papers and 158 participations in academic events

🧾 Conclusion:

Dr. Panagiota Tsiatsiou is a highly qualified and impactful researcher with significant contributions in hematology, molecular diagnostics, and public health. Her recent publications in Current Issues in Molecular Biology show scientific depth and relevance, especially regarding the clinical progression of COVID-19. She is an excellent candidate for a national or institutional Best Researcher Award, particularly in medical diagnostics and laboratory medicine.

Wei Zhang | Signal Transduction Mechanisms | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Wei Zhang | Signal Transduction Mechanisms | Best Researcher Award

Prof. Dr. Wei Zhang | Central South University | China

Dr. Wei Zhang, born on December 29, 1977, is a leading expert in clinical pharmacology and pharmacogenomics at the Institute of Clinical Pharmacology, Central South University, China. With over two decades of dedication to personalized medicine and drug-gene interaction research, Dr. Zhang has advanced the fields of pharmacokinetics, pharmacodynamics, and gut microbiome-pharmacology interactions. His global experience includes a research stint at the University of Maryland, USA. As a professor, scientific secretary, and associate dean, he contributes significantly to clinical research, translational pharmacogenomics, and academic leadership. Dr. Zhang has led multiple national research grants and published in top-tier journals like The Lancet, Nature Communications, and Signal Transduction and Targeted Therapy. His research bridges clinical pharmacology and precision medicine, with a particular focus on diabetes, cancer immunotherapy, and microbiome-drug interactions.

Publication profile:

Scopus

✅ Strengths for the Award:

  1. Outstanding Research Leadership
    Dr. Wei Zhang has served as a principal investigator for over 7 nationally funded projects, including China’s prestigious 863 Program and multiple NSFC grants. These projects span pharmacogenomics, clinical pharmacology, and personalized medicine, highlighting his leadership in cutting-edge translational research.

  2. Pioneering Work in Pharmacogenomics & Microbiome
    He has contributed significantly to the drug-gene-microbiota interaction field, especially in type 2 diabetes, cancer immunotherapy, and nephrotoxicity. His discoveries on SLCO1B1, TRIB3, OATP1B1, and CYP2A6 variations have direct implications for individualized therapy.

  3. Global Research Recognition
    His work is published in high-impact journals such as The Lancet, Nature Communications, Signal Transduction and Targeted Therapy, and Advanced Science. These publications attest to both quality and international relevance.

  4. Interdisciplinary Innovation
    Dr. Zhang bridges clinical pharmacology, bioinformatics, and microbial science, addressing unmet needs in precision medicine. His focus on gut microbiota’s role in drug efficacy and toxicity represents a visionary, interdisciplinary approach.

  5. Academic Mentorship & Leadership
    He has held senior academic roles (Professor, Associate Dean, Scientific Secretary), contributing to the development of academic programs and mentoring the next generation of clinical pharmacologists.

  6. Award-Winning Profile
    With over 9 prestigious national awards, including the New Century Talent Award, Henry Fok Young Teacher Award, and honors from the Chinese Ministry of Education, his contributions are officially recognized at the national level.

⚠️ Areas for Improvement:

  1. International Collaboration Expansion
    While Dr. Zhang has completed a visiting scholar stint in the U.S., expanding ongoing multi-national clinical collaborations (e.g., with EU or U.S. precision medicine centers) would further globalize his impact.

  2. Public Communication & Outreach
    His work is academically impactful but could benefit from greater visibility in public health or policymaking arenas, translating research findings into clinical guidelines or patient-accessible formats.

  3. Patents & Industry Translation
    While his academic output is prolific, increased technology transfer—e.g., pharmacogenetic diagnostics or drug screening tools—would further boost his profile as a translational scientist.

🎓 Education:

Dr. Wei Zhang obtained his entire academic education from Central South University in Changsha, Hunan, China. He earned his Ph.D. in Pharmacology (2003–2006) under the mentorship of Professor Hong-Hao Zhou, a member of the China Engineering Academy. His doctoral work centered on clinical pharmacology, with strong emphasis on drug assays and clinical trials. Prior to this, he received his M.A. in Pharmacology (2001–2003), focusing on pharmacogenomics and drug metabolism, gaining hands-on expertise in pyrosequencing and human DNA analysis. Dr. Zhang began his academic journey with a B.A. in Clinical Medicine (1996–2001) from XiangYa Medical School, where he built a solid foundation in pharmacology, physiology, and clinical medicine. This comprehensive academic trajectory laid the groundwork for his research in personalized therapy, pharmacogenetics, and pharmacokinetics, making him a key contributor in China’s pharmacological landscape.

🧪 Experience:

Dr. Wei Zhang currently serves as Professor at the Department of Clinical Pharmacology, Central South University, since 2013. Since 2009, he has also held the post of Associate Dean at the Institute of Clinical Pharmacology. Previously, he was an Associate Professor (2008–2013), Head of the Genetic Testing Laboratory (2007–2013), and Lecturer (2006–2008). He also contributes administratively as the Scientific Secretary of the National Key Discipline of Pharmacology since 2005. Dr. Zhang gained international experience as a Visiting Scholar at the University of Maryland, USA (2012–2013), further broadening his research expertise. Throughout his career, he has played a pivotal role in pharmacogenomic translation, clinical trials, and precision medicine development, mentoring students and managing large research teams. His leadership and administrative skills have contributed to elevating China’s presence in global pharmacology research.

🏅 Awards and Honors:

Dr. Wei Zhang’s distinguished career has been recognized with numerous prestigious awards. As a student, he received the “Class I Scholarship” and “Outstanding Postgraduate Student” awards in 2004 and 2005, followed by the “Excellent Report Award” from the Chinese Pharmacological Society in 2005. In 2006, he was named an Outstanding Graduate by Central South University. His research excellence earned him the “New Century Excellent Talents” award from the Chinese Ministry of Education in 2010 and the Science and Technology Prize of the Chinese Society of Pharmacy. He received international recognition in 2012 with a foreign fund from the China Scholarship Council. He was also honored as an “Outstanding Young Talent” by the Organization Department of China in 2013, and in 2014 received the esteemed “Henry Fok Young Teacher Award.” These accolades underscore his influential contributions to pharmacogenomics and clinical research in China.

🔬 Research Focus:

Dr. Wei Zhang’s research is centered around clinical pharmacology, pharmacogenomics, and drug-microbiome interactions, with a mission to enable personalized medicine. His work investigates the genetic and microbial determinants of drug efficacy, toxicity, and metabolism, especially in type 2 diabetes, cancer immunotherapy, and nephrotoxic drugs like cisplatin. He has led major national projects funded by the National Natural Science Foundation of China and the 863 Program, exploring the pharmacogenomic landscape and the gut microbiota’s impact on drug response. Dr. Zhang’s translational focus bridges laboratory findings to clinical application, utilizing genomic tools and bioinformatics to optimize therapy. His innovative research has unveiled how bacterial metabolites and transporters influence drug absorption and immune modulation, contributing significantly to the understanding of precision pharmacology. Through interdisciplinary collaborations, his work pushes boundaries in oncology, endocrinology, and microbiome science.

📚 Publications Top Notes:

  1. 🧬 SLCO1B1 variants and enalapril-induced cough – The Lancet (2015)

  2. 💉 TRIB3 Gln84Arg and vascular complications in T2DM – Lancet Diabetes & Endocrinology (2016)

  3. 🧠 Pharmacogenomics of hERG potassium channels – Trends in Molecular Medicine (2013)

  4. 🌱 Eubacterium rectale enhances anti-PD1 immunotherapy – Research (2023)

  5. 💊 Bacteroides ovatus and metformin-induced B12 deficiency – NPJ Biofilms Microbiomes (2023)

  6. 🧨 Cancer nanobombs enhancing PD-L1 expression – Advanced Science (2024)

  7. 🌿 Regulatory effects of herbal compounds on gut bacteria – Pharmacological Research (2023)

  8. 🔄 Drug–microbiota interactions in precision medicine – Signal Transduction and Targeted Therapy (2023)

  9. 🧫 Microbiota variation and ICI response – Nature Communications (2023)

  10. 🔬 Peptides from Sutterella potentiate PD-1 blockade – Gut (2024)

🧾 Conclusion:

✅ Recommendation: Highly Suitable for Best Researcher Award

Dr. Wei Zhang exemplifies the ideal candidate for the Best Researcher Award. His robust scientific portfolio, pioneering work in pharmacogenomics and drug–microbiota interaction, along with his leadership in both academia and national projects, demonstrate excellence, innovation, and long-term impact. While further expansion into international policy or industry translation could enhance his reach, his current achievements already position him at the forefront of clinical pharmacology and personalized medicine in China and globally.

Tao Liang | Cell Death Pathway | Best Researcher Award

Published on by Cell Biologist

Mr. Tao Liang | Cell Death Pathway | Best Researcher Award

Mr. Tao Liang, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, China

Dr. Tao Liang is an accomplished medicinal chemist with deep expertise in small molecule drug design, synthesis, and pharmacological evaluation. Originating from Dancheng County, Henan Province, and currently residing in Wuhu City, Anhui Province, Dr. Liang is an Assistant Researcher at The Second Affiliated Hospital of Wannan Medical College. He earned his Doctor of Medicine from Shandong University, a leading institution under China’s “Double First-Class” initiative. With over 7 first-author SCI publications and multiple national invention patents, his research significantly contributes to targeted cancer therapies, especially involving HDAC6-selective inhibitors and Bax agonists. He has successfully led key projects funded by the Anhui Provincial Government and participated in prestigious National Natural Science Foundation of China projects. Known for both scientific depth and innovation, Dr. Liang has been recognized with national-level scholarships and university-wide honors for outstanding research achievements and academic excellence.

Publication Profile:

Orcid

✅ Strengths for the Award:

  1. High-Impact Publications

    • Authored 7 first-author SCI papers, including publications in top-tier journals like Acta Pharm Sin B (IF 14.907) and J Med Chem (IF 8.039).

    • Published extensively on HDAC6 isoform-selective inhibitors and apoptosis-targeting small molecules, a niche and cutting-edge domain in anticancer drug research.

  2. Research Leadership & Innovation

    • Serves as Principal Investigator for two key provincial research projects focusing on selective cancer therapies.

    • Demonstrated innovation in designing dual-target inhibitors (MMP/HDAC) and novel Bax agonists.

  3. National-Level Collaborations

    • Participated in major National Natural Science Foundation of China projects (5 total), totaling over RMB 2 million in funding.

    • Engaged with multidisciplinary teams and key opinion leaders, including renowned researchers such as Prof. Hao Fang and Prof. Xuben Hou.

  4. Academic Recognition

    • Winner of prestigious honors such as the National Scholarship, Outstanding Doctoral Graduate, and guest speaker at elite academic forums.

    • Recipient of 15+ national and university-level awards, including innovation prizes and scholarships.

  5. Patent Contributions

    • Holds 4 national invention patents, reflecting translational potential and real-world application of his research outputs.

🔧 Areas for Improvement:

  1. International Visibility & Collaboration

    • Current research impact is primarily within domestic circles (China). Engaging in cc, postdoctoral exchanges, or publishing with international co-authors would elevate recognition.

  2. Clinical Translation Pipeline

    • Despite strong preclinical development, there is no direct evidence of transition to clinical trials or industrial commercialization. Partnering with biotech/pharma could increase translational outcomes.

  3. Leadership Beyond Research

    • As an early-career researcher, administrative leadership (e.g., lab director, national committee memberships) may still be developing. Building a research group or mentoring PhD students would strengthen this.

  4. Interdisciplinary Expansion

    • Expertise is strong in medicinal chemistry, but cross-disciplinary projects involving AI/drug discovery, systems biology, or clinical oncology could broaden the impact.

🎓 Education:

Dr. Tao Liang received his Bachelor of Science in Pharmacy from Shandong University (2013.9–2017.6), one of China’s elite institutions under the National “985 Project” and “Double First-Class” initiative. Continuing at the same university, he pursued a Master’s and Ph.D. in Medicinal Chemistry, earning a Doctor of Medicine degree in 2022. Shandong University, renowned for its Ministry of Education Class A-rated disciplines, provided Dr. Liang with a rigorous scientific environment and access to state-of-the-art research facilities. During his academic training, he developed a strong foundation in chemical biology, natural product synthesis, and drug development. His educational journey has been marked by consistent excellence, earning him accolades like National Scholarships and Outstanding Graduate awards. His academic credentials and extensive research during his Ph.D. have positioned him as a leading young researcher in the field of medicinal chemistry in China.

💼 Work Experience:

Since August 2022, Dr. Tao Liang has been serving as an Assistant Researcher at The Second Affiliated Hospital of Wannan Medical College. His research focuses on the structural design, chemical synthesis, and pharmacological activity evaluation of small molecule drugs, particularly targeting HDAC isoforms and apoptotic regulators like Bax. He currently leads two key projects: one on HDAC6-selective inhibitors and another on Bax agonists for cervical cancer therapy, funded by the Anhui Provincial Higher Education and Health Commission respectively. Previously, he participated in several high-impact national research projects, including two funded by the National Natural Science Foundation of China, focusing on anti-cancer drug discovery. His roles have involved both independent project leadership and critical collaboration within multidisciplinary teams. Dr. Liang’s work experience showcases his capabilities in translational medicinal chemistry research and positions him as a promising talent in pharmaceutical innovation.

🏆 Awards and Honors:

Dr. Tao Liang has received more than a dozen honors for his outstanding academic and research contributions. These include the prestigious National Scholarship (2021), Outstanding Doctoral Graduate of Shandong University (2022), and multiple first-class scholarships throughout his postgraduate studies. He was a special guest speaker at prominent forums like the “Haiyou Doctoral Forum” and “Lao Xu Talks about High Strategies.” His undergraduate years were equally distinguished, earning the first prize in the ‘Challenge Cup’ and honors like “Outstanding Graduate” and “Excellent Communist Youth League Member”. His early career was also decorated with international recognitions such as the First Prize for Innovation Results at the World University Students’ Pharmaceutical Garden Forum. These awards highlight both his academic brilliance and commitment to scientific advancement, affirming his eligibility and strength as a nominee for the Best Researcher Award.

🔬 Research Focus:

Dr. Tao Liang’s research centers on the design, synthesis, and biological evaluation of small molecule inhibitors with a primary focus on histone deacetylase 6 (HDAC6) isoform-selective inhibitors and Bax agonists for cancer therapy. His work integrates computational modeling, medicinal chemistry, and pharmacodynamics to create targeted therapies aimed at epigenetic modulation and apoptosis induction in cancer cells. He has actively contributed to national-level projects exploring dual-target inhibitors (MMP/HDAC) and small molecule interventions for Mcl-1 and striatal enriched tyrosine phosphatase (STEP) targets. Dr. Liang is particularly recognized for his innovation in optimizing chemical scaffolds for selective inhibition and minimizing off-target effects. Through collaborative and independent research, he aims to address challenges in chemotherapeutic resistance and toxicity. His scientific pursuits align with current global trends in precision oncology, making significant strides in targeted therapy development and laying a foundation for future clinical translation.

📚 Publications Top Notes:

  1. 📘 Design, synthesis and evaluation of structural optimization derived HDAC6 isoform-selective inhibitor – Bioorganic Chemistry, 2025

  2. 📗 Targeting histone deacetylases for cancer therapy: Trends and challenges – Acta Pharmaceutica Sinica B, 2023

  3. 📙 Potential applications of BPFP1 in Bcl-2 protein quantification, carcinoma cell visualization, cell sorting and early cancer diagnosis – European Journal of Medicinal Chemistry, 2021

  4. 📕 Design, synthesis and biological evaluation of 3,4-disubstituted-imidazolidine-2,5-dione derivatives as HDAC6 selective inhibitors – European Journal of Medicinal Chemistry, 2021

  5. 📘 Recent Development of Novel HDAC6 Isoform-selective Inhibitors – Current Medicinal Chemistry, 2021

  6. 📗 HDAC–Bax Multiple Ligands Enhance Bax-Dependent Apoptosis in HeLa Cells – Journal of Medicinal Chemistry, 2020

  7. 📙 Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors – ACS Medicinal Chemistry Letters, 2019

  8. 📕 Synthesis and Antiproliferative Activity of Thiadiazole Peptidomimetic Derivatives – Chinese Journal of Organic Chemistry, 2016

🧾 Conclusion:

Dr. Tao Liang is highly suitable for the Best Researcher Award, especially in the early- to mid-career researcher category. His extensive publication record, innovative medicinal chemistry work, leadership in funded projects, and impressive academic recognitions make him an exemplary candidate.

Wen Li | Tissue Engineering Regeneration | Best Researcher Award

Published on by Cell Biologist

Mr. Wen Li | Tissue Engineering Regeneration | Best Researcher Award

Mr. Wen Li , State key laboratory of supramolecular structure and materials, college of chemistry, Jilin University , China

Professor Wen Li is a leading scientist at the College of Chemistry, Jilin University, recognized for his contributions to peptide- and protein-based bioactive materials. Earning his Ph.D. from Jilin University in 2006, he rapidly advanced through academic ranks—from lecturer to full professor by 2013. His academic journey also includes postdoctoral research at Seoul National University, South Korea. Professor Li’s interdisciplinary research integrates chemistry, materials science, and biomedical applications, positioning him as a pioneering figure in supramolecular chemistry and bioinspired adhesives. With numerous high-impact publications and innovations in antimicrobial peptides, tissue sealants, and soft electronics, he has significantly contributed to both scientific knowledge and real-world biomedical applications. His commitment to translating fundamental research into functional materials continues to drive breakthroughs in sustainable, degradable, and biocompatible materials.

Publication Profile:

Orcid

✅ Strengths for the Award:

  1. Outstanding Academic Progression

    • From Ph.D. completion in 2006 to full professorship by 2013, Professor Wen Li has shown rapid and consistent academic advancement.

    • He has international research exposure through his postdoctoral work at Seoul National University.

  2. High-Impact Research Contributions

    • Published extensively in top-tier journals such as Angewandte Chemie, Biomaterials, Advanced Healthcare Materials, Langmuir, and Journal of Materials Chemistry.

    • His research is highly interdisciplinary, linking peptide self-assembly, biomaterials, antimicrobial systems, and energy devices.

  3. Real-World Impact & Innovation

    • Developed cutting-edge bioadhesives, nano-antimicrobial systems, and biodegradable materials with significant medical and environmental relevance.

    • Strong emphasis on sustainability, biocompatibility, and smart responsive materials like redox or photo-controlled systems.

  4. Leadership and Collaboration

    • Leads a productive research group, mentoring young scientists and collaborating across multiple institutions.

    • His publications include a large network of co-authors, showing evidence of team science and academic collaboration.

  5. Diverse Research Outputs

    • Contributions span various formats: fundamental studies, applied innovations, material designs, and medical applications.

    • From self-healing hydrogels to stretchable supercapacitors, his portfolio is both deep and diverse.

⚠️ Areas for Improvement:

  1. Commercial and Clinical Translation

    • While the foundational work is strong, more efforts toward industrial partnerships and clinical trials would increase real-world adoption.

    • Filing patents or working with biotech/medical device companies could help scale his research outcomes.

  2. Global Visibility

    • Greater involvement in international conferences, editorial boards, or global initiatives can further enhance his global academic footprint.

    • Collaborative projects with top labs outside Asia could diversify perspectives and increase influence.

📘 Education:

Wen Li received his Ph.D. in Chemistry from Jilin University in 2006, a prestigious institution known for its advanced research in materials and chemical sciences. His doctoral studies focused on supramolecular structures, laying the foundation for his career in peptide and polymer-based materials. The rigorous academic environment at Jilin University equipped him with deep insights into molecular interactions, material fabrication, and biomedical chemistry. After completing his Ph.D., he expanded his academic perspective by pursuing postdoctoral research at Seoul National University (2010–2011), one of South Korea’s top-tier research universities. There, he collaborated on interdisciplinary projects that fused chemistry with nanotechnology and biomaterials. This international experience enriched his scientific worldview and further refined his expertise in designing functional peptide-based assemblies. His academic training bridges the gap between molecular chemistry and real-world applications, particularly in the biomedical and environmental sectors.

👨‍🔬 Experience:

Professor Wen Li began his academic career as a lecturer at the State Key Laboratory of Supramolecular Structures and Materials, Jilin University, immediately after receiving his Ph.D. in 2006. By 2008, he was promoted to Associate Professor due to his early contributions to peptide-based material science. Between 2010 and 2011, he broadened his research capabilities as a postdoctoral fellow at Seoul National University, where he engaged in collaborative research on supramolecular assemblies and nano-biotechnology. Returning to Jilin University, he became a full professor in September 2013, leading a dynamic research group dedicated to cutting-edge biomaterials and soft electronics. With over 15 years of academic and research experience, Professor Li has mentored numerous graduate students, secured significant research grants, and maintained a strong publication record. His career trajectory reflects continuous advancement in leadership, interdisciplinary collaboration, and innovation in bioinspired materials.

🔬 Research Focus:

Professor Wen Li’s research centers on the design and fabrication of peptide- and protein-based bioactive materials with applications in healthcare and sustainability. His work explores self-assembling nano-antimicrobial peptides, biomimetic underwater adhesives, tissue sealants, and flexible hydrogel electronics, integrating supramolecular chemistry with biomedical engineering. A notable strength of his research lies in creating multifunctional materials that are not only biocompatible and degradable but also smart and responsive, such as photo-switchable or redox-reactive assemblies. His group develops materials that perform complex biological tasks—like sealing tissues, healing wounds, or delivering antimicrobial activity—while maintaining eco-friendly characteristics. Recent efforts also include bio-plastics and adhesive tapes for surgical and environmental use. Professor Li’s innovations address pressing challenges in medical technology and sustainability, aiming for materials that are both high-performing and environmentally conscious. His work bridges disciplines and has wide-ranging impact across chemistry, medicine, and green materials science.

📚 Publications Top Notes:

  1. 🧬 Polyoxometalate-Driven Self-Assembly of Short Peptides into Multivalent Nanofibers with Enhanced Antibacterial Activity – Angew. Chem. Int. Ed. (2016)

  2. 🔦 Host–Guest Interaction Driven Peptide Assembly into Photoresponsive 2D Nanosheets with Switchable Antibacterial Activity – CCS Chem. (2021)

  3. 🧪 Nano-Antimicrobial Peptides Based on Constitutional Isomerism-Dictated Self-Assembly – Biomacromolecules (2022)

  4. 🧲 Exploiting Redox-Complementary Peptide/Polyoxometalate Coacervates for Spontaneously Curing into Antimicrobial Adhesives – Biomacromolecules (2022)

  5. 💧 Wet and Functional Adhesives from One-Step Self-Assembly of Amino Acids and Polyoxometalates – Angew. Chem. Int. Ed. (2017)

  6. 🩹 Peptide/Glycyrrhizic Acid Supramolecular Polymer: A Medical Adhesive for Dural Sealing – Biomaterials (2023)

  7. 🌿 Plant Protein-Peptide Supramolecular Polymers for Surgical Sealing – Adv. Healthcare Mater. (2023)

  8. ⚙️ Protein-Based Supramolecular Adhesive with On-Demand Adhesion for Preventing Tissue Adhesion – Chem. Eng. J. (2025)

  9. 🔋 Embedding Hydrogel Electrodes for Stretchable High-Performance Supercapacitors – Chem. Eng. J. (2024)

  10. 🧼 Advances in Peptide/Polymer Antimicrobial Assemblies – J. Mater. Chem. B (2025)

🧾 Conclusion:

Professor Wen Li is a highly deserving candidate for the Best Researcher Award. His research addresses critical scientific and societal challenges, such as antimicrobial resistance, surgical innovation, and eco-friendly material development. He combines rigorous chemistry with creative engineering, producing solutions that are both scientifically novel and practically viable.